In a patient with dengue fever who has elevated hepatic enzymes, what is the acute condition diagnosed as?

Dengue-Associated Hepatitis

When hepatic enzymes are elevated during dengue fever, this acute condition is diagnosed as dengue-associated hepatitis or dengue hepatitis. This represents a spectrum of liver involvement that ranges from mild transaminase elevation to severe hepatitis and, rarely, acute liver failure 1, 2.

Clinical Spectrum and Diagnosis

Liver involvement in dengue is extremely common, with transaminase elevation occurring in virtually all dengue patients 2. The condition manifests as:

• Mild to moderate elevation: Most common presentation with AST and ALT increases that correlate with disease severity markers
• Severe hepatitis: Marked transaminase elevation (AST often >1000-2000 U/L) with potential for hepatic dysfunction 1, 3
• Acute liver failure: Rare but life-threatening complication characterized by hepatic encephalopathy, coagulopathy, and multiorgan dysfunction 4, 5, 6

The diagnosis is made clinically in the context of confirmed dengue infection (positive NS1 antigen or dengue NAAT/IgM) combined with elevated liver enzymes 7, 3. According to the 2009 WHO classification referenced in guidelines, dengue is categorized as 'without warning signs,' 'with warning signs,' or 'severe' 8.

Key Diagnostic Features

The pattern of liver injury in dengue has characteristic features:

• AST typically exceeds ALT (unlike typical viral hepatitis where ALT > AST)
• Peak enzyme values usually occur later than other dengue complications 2
• Transaminase levels can reach several thousand IU/L in severe cases 1, 3
• Elevated AST and ALT occur in 72.26% and 46.85% of hospitalized patients respectively 9

Critical Differential Diagnosis

You must exclude other causes of acute hepatitis before attributing liver injury solely to dengue 10. The differential includes:

• Viral hepatitis: HAV, HEV, HBV, HCV, EBV, CMV, HSV 10, 11
• Drug-induced liver injury (DILI): Review all medications and supplements 10
• Autoimmune hepatitis: Can present acutely with similar features 12
• Wilson's disease: Especially in younger patients with acute presentation 13
• Ischemic hepatitis: Consider in shock states 11

Important Clinical Pitfalls

Chronic hepatitis B co-infection is associated with modestly but significantly increased ALT levels in dengue patients 2. However, this does not substantially alter the clinical picture or outcome.

Clinically severe liver involvement in dengue is infrequent and idiosyncratic, but when it occurs, it usually results in severe bleeding 2. The combination of thrombocytopenia (from dengue) and hepatic coagulopathy creates particularly high hemorrhagic risk.

Temporal Evolution

A critical point: transaminase elevation in dengue typically peaks AFTER other complications have already manifested 2. This means you cannot rely on liver enzymes as an early warning sign. Monitor for warning signs of severe dengue (abdominal pain, persistent vomiting, fluid accumulation, bleeding, lethargy) regardless of current transaminase levels.

Management Approach

Management remains primarily supportive 1, 4, 5:

1. Fluid management: Careful balance to avoid both hypovolemia and fluid overload
2. Avoid hepatotoxic medications: Including NSAIDs (also contraindicated due to bleeding risk)
3. Monitor for complications: Hepatic encephalopathy, coagulopathy, acute kidney injury
4. Correct coagulopathy: Fresh frozen plasma, cryoprecipitate as needed
5. Consider N-acetylcysteine: Emerging evidence suggests potential benefit in severe cases 1, 6, though this is not yet standard of care

For acute liver failure (hepatic encephalopathy + coagulopathy), immediate referral to a liver transplant center is mandatory 12.

Prognosis

The clinical course is generally favorable with transaminase normalization in 95.5% of cases, with mean recovery time of 13 days 9. However, patients with hypertension have a 2.3-fold higher risk of developing hepatic cytolysis 9.

The case-fatality rate in hospitalized dengue patients with liver involvement is approximately 7% 9, emphasizing the need for vigilant monitoring and aggressive supportive care when severe hepatitis develops.